Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 2
Submit an article Journal homepage
269
Views
17
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions

Pieter MartensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; Correspondence[email protected]
View further author information
,
Seppe LambeetsDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Chirik Wah LauDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Matthias DupontDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
&
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumView further author information
Pages 115-122 | Received 26 Mar 2018, Accepted 24 Apr 2018, Published online: 17 Jun 2018

References

  • McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
  • The SOLVD Investigators, Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
  • McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in eart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16:817–825.
  • Martens P, Belien H, Dupont M, Mullens W. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail. 2018;5:275–283.
  • Collier TJ, Pocock SJ, McMurray JJ, et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J. 2013;34:2823–2829.
  • Martens P, Vercammen J, Ceyssens W, et al. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. ESC Heart Fail. 2018. DOI:10.1002/ehf2.12248
  • Packer M, Armstrong WM, Rothstein JM, et al. Sacubitril-Valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735–736.
  • Desai AS, Solomon S, Claggett B, et al. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circ Heart Fail. 2016;9:e002735.
  • Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576–2584.
  • Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18:1228–1234.
  • Simpson J, Jhund PS, Silva CJ, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66:2059–2071.
  • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.